A research study on the use of magic mushrooms in Canada revealed that nearly 80% of the participants support the idea of psilocybin, a substance found in these mushrooms, being used as a medical treatment for those in distress. Moreover, about two-thirds of these Canadian participants agreed that psilocybin should be legally accessible for those who need it.
Aside from advocating for easier availability of the substance, an impressive 84.8 percent of the participants expressed their belief that such therapies’ costs should be covered by the public health system. A majority of Canadians recognize psilocybin as a feasible solution, especially for treating end-of-life distress.
[toc]
Main Takeaways:
- Residents from Québec, Ontario, Alberta, and British Columbia view psilocybin as a valid medical alternative for managing end-of-life existential distress.
- Magic mushrooms are regarded as a safe option for treating existential distress.
- Participants in two double-blind trials reported immediate and long-lasting benefits, with effects enduring for six months or more.
Exploring Existential Distress
Existential distress, also known as existential suffering, spiritual distress, and demoralization, arises when individuals grapple with the reality of their mortality. Patients may experience feelings of helplessness, isolation, anxiety, and a loss of meaning and purpose. This distress is especially prevalent among patients with life-threatening illnesses and can even lead to suicidal contemplation or a desire to hasten death.
Typically, those struggling with terminal illnesses or significant life changes are most likely to experience this form of distress. It can have a profound impact on their mental health and overall quality of life.
Existential therapy aims to address issues like anxiety, depression, grief, loneliness, apathy, despair, confusion about identity, feelings of purposelessness, and existential fear. However, it might require several sessions and may not prove effective for everyone.
The uncertainty regarding the effectiveness of traditional therapy is a main reason why many individuals look for alternative treatments.
Health Canada’s Stance on Psilocybin for Therapeutic Use
Over the last two decades, preliminary clinical trials have highlighted the potential advantages of psychedelic substances in tackling complex mental health conditions. Specifically, psilocybin has demonstrated quick and sustained relief from existential distress in patients approaching the end of life.
Recognizing the possible effectiveness of these proposed hallucinogenic mushrooms, especially when conventional treatments are insufficient, Health Canada revised the Special Access Program in 2022. This revision allows medical practitioners to request controlled substances for their patients.
Canadians’ Advocacy for Psilocybin Access
A study published in the Palliative Care Journal evaluates societal viewpoints on psilocybin-assisted therapy for end-of-life care. The study’s data encompasses:
| Methodology | Input from 2,800 Canadians from Québec, Ontario, Alberta, and British Columbia. 19% of these participants had previously used psilocybin (15% in Québec, 26% in British Columbia). |
| Findings | 79.3% regard psilocybin-assisted therapy as a legitimate medical option for treating end-of-life existential distress. 63.3% believe psilocybin should be integrated into medical treatment. 84.8% endorse the delivery of this therapy by the public health system. 44.2% believe healthcare professionals should administer the substance without Health Canada’s supervision. |
These outcomes align with surveys conducted in Canada, England, and Australia. The researchers underscored that their study is distinctive because it focuses on the use of psychoactive substances for managing existential distress in end-of-life situations.
Reasons for Canadian Advocacy of Psilocybin Use
An increasing number of Canadians support the use of psilocybin for therapy, primarily driven by findings from esteemed research organizations. Another influential factor is the perceived safety of psilocybin mushrooms in relieving existential distress. Subjects across various studies have not reported severe adverse health effects, such as multi-organ failure.
| Study | Method | Results |
| Johns Hopkins Study | 51 patients were administered a high dose of psilocybin and a low dose as an active placebo control | Immediate and enduring |
| The benefits of this therapy can last for six months or more. Its effectiveness is primarily due to mystical experiences that foster a sense of unity and deep emotional understanding. | ||
| Trial at New York University | 29 patients were randomly chosen to receive either psilocybin or the active placebo niacin. | The results reflected those of the Johns Hopkins study. Participants who received psilocybin reported psychological relief and a better outlook on life and death. |
| BMC Palliative Care | Nineteen participants, including 7 doctors, 4 practicing nurses, 4 chaplains, 3 social workers, and a psychologist, were interviewed. The study aimed to comprehend how palliative care professionals interpret existential distress and their perceptions of psychedelic therapy as a treatment method. | Palliative care practitioners suggested that psychedelic-assisted therapy (PAT) has potential in reducing existential distress. |
Patient Experiences
Beyond scientific studies, numerous patient stories also affirm the effectiveness of psilocybin in improving mental health and overall quality of life.
The Journey of Yokoi
Mio Yokoi, who was diagnosed with terminal stage 4 pancreatic cancer, shares a transformative experience during her assisted therapy. She visualizes herself on a raft surrounded by nature and imaginative creatures. This vision instilled in her a deep sense of the universe’s interconnectedness and support, providing her with immense peace and validation.
Despite receiving conventional mental health support, Yokoi continued to suffer from severe anxiety and distress following her diagnosis. Psilocybin therapy allowed her to reconnect with her body and provided a tangible sense of love and support. This significantly improved her emotional and mental health.
Story of Chrissy
Chrissy, a woman in her 50s, battled stage 4 breast cancer that had metastasized to her lungs. She was working full-time as an administrative supervisor in healthcare when the study was conducted and identified herself as an atheist. She was diagnosed with Generalized Anxiety Disorder during her screening.
Chrissy experienced significant reductions in her levels of anxiety, depression, fear of death, hopelessness, and demoralization. When asked about any changes in her religious or spiritual beliefs following her therapy session, she stated that the experiences had brought a sense of purpose and reality to her beliefs.
Brenda’s Journey
Brenda, a female in her mid-sixties, was diagnosed with stage I colon cancer. During her health screening, it was discovered that she had never consumed hallucinogens. Moreover, she fulfilled the diagnostic criteria for Chronic Adjustment Disorder, which was further complicated by Anxiety.
In the course of her therapy, Brenda experienced the sensation of dying on two occasions. However, these experiences led her to perceive death not as something to fear, but as a beautiful transition in the cycle of existence. Acknowledging that the study sparked her healing journey from past trauma, her responses reflected a profound transformation.
Her fear of death and anxiety diminished, while her sense of spirituality intensified, as evidenced by her data.
Availability of Magic Mushroom Products in Canada
The current availability of psilocybin capsules and other such products, designed to alleviate existential distress and other psychological issues, may be limited. However, reliable online dispensaries remain an excellent source for procuring these products when necessary.
| Characteristic | Brazilian Psilocybe Cubensis | Cambodian Psilocybe Cubensis | Melmac Psilocybe Cubensis |
| Origin | Native to Brazil and some surrounding South American countries. | Discovered in Cambodia, specifically around the Angkor Wat Temple. | Closely related to the popular Penis Envy mushrooms, which rose to prominence in the 1970s. |
| Potency | Moderate potency, proving suitable for beginners. | Also of moderate potency, making it ideal for those new to the experience. | Highly potent; recommended for individuals with intermediate to advanced experience. |
| Effects | Can cause a mental high, mild disorientation, enhanced perception of colors, feelings of euphoria, spiritual experiences, enhanced creativity, and improved focus. | Known to induce an energizing, long-lasting high, minor visual changes, increased creativity, feelings of joy, a gentle physical high, fractal imagery, and sensations of happiness. | Can lead to profound shamanic experiences, vision quests, intense mystical encounters, increased creativity, focus, social awareness, and mood enhancement. |
Using Psilocybin Products to Ease End-of-life Discomfort
Existential or end-of-life distress can impose a significant burden on patients nearing the end of their lives. Traditional remedies often fail to offer sufficient relief, prompting a growth in Canadian advocacy for easier public healthcare access to magic mushrooms. This increased public interest could We advocate for regulatory authorities to recognize magic mushrooms as a potential treatment option. Acquire your psychedelics and mushroom delivery from Shroom Delivery Canada.
Frequently Asked Questions
What should patients expect from Psilocybin-Assisted Therapy?
Patient outcomes from Psychedelic-assisted therapy (PAT) can greatly differ, making meticulous preparation and strict adherence to certain steps crucial for a positive result. Patients must undergo rigorous screening and mental readiness prior to ingesting the substance.
- Pre-Session Preparation: Patients undergo a detailed evaluation. The therapist discusses the patient’s goals and expectations to set the stage for the session. They also explain the potential effects of the process and what the patient can expect during the session.
- The Session Itself: Patients receive a controlled dosage of the substance in a conducive, distraction-free environment to promote relaxation and self-reflection. The therapist is present throughout to offer continuous support and guidance.
- Post-Session Integration Therapy: This therapy helps patients comprehend and assimilate their experiences. Further sessions provide continuous support and therapy to reinforce the insights and changes achieved during the therapy.
How does psilocybin affect the brains of distressed patients?
Psilocybin interacts with the brain by binding to serotonin receptors, particularly the 5-HT2A receptor. This interaction can result in alterations in perception, mood, and cognition, leading to considerable shifts in consciousness, emotional insights, and new viewpoints.
Is psilocybin therapy available to everyone?
Psilocybin therapy is not appropriate for everyone. Patients with certain mental health conditions or existential distress are thoroughly screened to exclude those with a history of psychosis.
Related Articles:
